complicado mecanismo de acción antitumoral como con sus efectos .. inhibidores de la topoisomerasa II (doxorrubicina, etopósido. mecanismo de acción de antineoplasicos. AV Doxorrubicina (antraciclina). – Lesión del ADN. –Inhibición topoisomerasa II. –Vía intravenosa. Abraxane (nombre genérico: paclitaxel unido a albúmina (nab-paclitaxel)) · Adriamicina (nombre genérico: doxorrubicina) · Carboplatino.
|Published (Last):||28 July 2011|
|PDF File Size:||20.18 Mb|
|ePub File Size:||11.1 Mb|
|Price:||Free* [*Free Regsitration Required]|
As this can be a progressive injury, appropriate long-term follow-up is required. Oncology Huntingt ;12 1 Suppl 1: Extravasation of epirubicin infusions should be avoided.
Additionally, the free radicals crosslink sulfhydryl groups of dxorrubicina channels and inhibit Ca-ATPase which leads to extensive depletion of sarcoplasmic reticulum SR calcium stores and prevents restoration of calcium stores in the SR, respectively. Br J Cancer ; An increased incidence of ventricular dysfunction and congestive heart failure has been associated with the concurrent use of trastuzumab with anthracyclines e.
Men may experience spermatogenesis inhibition.
The epirubicin combination was significantly more myelosuppressive. Age does affect the clearance of epirubicin in female patients. Women may experience irreversible amenorrhea, premature menopause, and decreased fertility. If possible, avoid veins over joints or in extremities with compromised venous or lymphatic drainage.
There was a problem providing the content you requested
The esophagus can be especially sensitive. The common dose for bladder cancer prophylaxis following TUR is epirubicin 50 mg in 50 ml sterile normal saline instilled into the bladder once weekly for 4 weeks then maintenance treatement of the same dose monthly for 11 months. Epirubicin-derived free mecanismp can induce membrane lipid peroxidation, DNA strand scission, and direct oxidation of purine or pyrimidine bases, thiols and amines.
She experienced a spontaneous abortion. Two cases of acute lymphoid leukemia ALL have been reported in patients receiving epirubicin. Passive immunoprophylaxis with immune globulins may be indicated for immunocompromised persons instead of, or in addition to, vaccination.
Epirubicin may contribute to gonadal suppression seen during cancer chemotherapy. Due acciln the thrombocytopenic effects of epirubicin, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, strontium chloride, and thrombolytic agents.
Cyclosporine can be given to block MDR resistance in doses much higher than those used in transplantation. The overall survival following both regimens was not superior to other treatments. Due to the risk of long-term cardiotoxicity, it has been recommended that children treated with anthracyclines should undergo screening with ECGs and echocardiograms every 2 years and hour continuous ECGs and radionucleide angiograms every 5 years.
Administration of epirubicin to patients who have received the maximum cumulative dose of other anthracycline agents e. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced dee cancer: Epirubicin may also form complexes with iron or copper. The majority of patients were then able to undergo surgical resection.
Signs of myelosuppression include pancytopenia, leukopenia, neutropenia, thrombocytopenia, and anemia.
Eur J Cancer ; It is thought that myocardial damage and ventricular dysfunction progress and lead to late-onset cardiac dysfunction following treatment with doxorrbicina. Patients who have received adjuvant epirubicin in clinical trials show a cumulative risk of secondary acute myelogenous leukemia of about 0.
EPIRUBICINA EN VADEMECUM
Dosage adjustments are required for patients with hepatic or renal dysfunction. It cacion not known if epirubicin is excreted in human breast milk but has been detected in breast milk of animals.
Patients with prior treatment with radiation therapy or anthracyclines may have axcion ability to tolerate trastuzumab therapy. Some antineoplastic agents have been reported to decrease the absorption of digoxin tablets due to their adverse effects on the GI mucosa; no significant change was seen with digoxin capsules, and the effect on digoxin liquid is not known.
Intramuscular administration and subcutaneous administration of epirubicin are contraindicated due to severe skin and tissue necrosis. Venous sclerosis may result from the injection of epirubicin into small vessels or repeated injection into the same vein.
Live virus vaccines are contraindicated doxorrubiclna therapy with antineoplastic axcion due to the potentiation of virus replication, adverse reactions to the virus, and the immunocompromised status of the patient. Clinicians should consult the appropriate references to verify the dose. The estimated risk of developing epirubicin-induced CHF is 0. Despite these dose increases, the immune response may still be suboptimal. Those undergoing chemotherapy should not be exposed to others who have recently received the oral poliovirus vaccine OPV.
However, later events several months to years after ending treatment have been reported.
Tumor lysis syndrome may occur due to treatment with epirubicin; appropriate measures e. Epirubicin-induced cardiomyopathy and congestive heart failure CHF is associated with the cumulative dose of epirubicin.
Medicamentos de quimioterapia
Accino effects of epirubicin can increase the risk of infection or bleeding; therefore, dental work should be delayed until blood counts have returned to normal. Patients who have already received the maximum cumulative dosage of anthracyclines should not receive intravesicle epirubicin. Epirubicin-induced free radical formation contributes to its cardiotoxicity.
The resulting hyperuricemia could aggravate gout or urate nephrolithiasis. These complexes have high association constants and may contribute to epirubicin-induced cardiotoxicity by enhancing redox cycling to produce membrane and mitochondria damage. J Clin Oncol ; Attempt to aspirate the drug prior to removing the needle.